ArticleAnnals of surgical oncology2026
A Population Based Analysis of Breast Cancer Outcomes Among Disaggregated Asian American and Pacific Islander Women.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Not all Asian American and Pacific Islander Breast Cancer is the Same: The Need for Routine Population Data Disaggregation.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer incidence is rising among Asian women, yet aggregation of Asian American and Pacific Islander (AAPI) populations obscures meaningful subgroup differences. This study evaluated tumor biology, treatment patterns, and overall survival (OS) among disaggregated AAPI subgroups.
methodsUsing the National Cancer Database, we identified AAPI women with stage I-III invasive breast cancer diagnosed from 2004 to 2021, disaggregated into East Asians (EA), Southeast Asian (SE), South Asian (SA), and Pacific Island (PI) women. Descriptive statistics, log-rank tests, multivariable Cox regression, and Kaplan-Meier estimates were used.
resultsA total of 72,253 AAPI women met the inclusion criteria: EAs 40%, SEAs 30%, SAs 21%, and PIs 8%. PIs had the highest comorbidity burden, lowest private insurance rates, and greatest travel burden (31% lived >20 miles from their treatment center). Tumor biology differed by subgroup: PIs had the highest Luminal A prevalence (61% vs. 54-58%), SEAs had higher human epidermal growth factor receptor 2-positive rates (5.0% vs. 3.2-3.8%), and SAs had the highest triple-negative rate (9.4% vs. 5.8-7.3%). EAs had the highest proportion of stage I disease (62% vs. 56-57%). PIs were least likely to receive hormone therapy among hormone receptor-positive patients (82% vs. 85-86%) and adjuvant radiation after lumpectomy (82% vs. 84-85%). Ten-year OS was 84% (EAs), 86% (SAs), 84% (SEAs), and 75% (PIs) (p<0.01); Cox regression confirmed the highest mortality risk among PIs (hazard ratio 1.4; 95% confidence interval 1.3-1.5, p<0.01).
conclusionsDespite more favorable tumor biology, PI women experienced the poorest OS, underscoring the need for subgroup-specific strategies to improve access, treatment, and outcomes.
Indexed as
Identifiers
42632876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.